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The renal renin–angiotensin system plays a major role in
determining the rate of chronic renal disease progression.
Treatment with activators of the vitamin D receptor retards
the progression of experimental chronic renal disease, and
vitamin D is known to suppress the renin–angiotensin system
in other organs. Here we determined if the beneficial effects
of paricalcitol (19-nor 1,25-dihydroxyvitamin D2) were
associated with suppression of renin–angiotensin gene
expression in the kidney. Rats with the remnant kidney
model of chronic renal failure (5/6 nephrectomy) were given
two different doses of paricalcitol thrice weekly for 8 weeks.
Paricalcitol was found to decrease angiotensinogen, renin,
renin receptor, and vascular endothelial growth factor mRNA
levels in the remnant kidney by 30–50 percent compared to
untreated animals. Similarly, the protein expression of renin,
renin receptor, the angiotensin type 1 receptor, and vascular
endothelial growth factor were all significantly decreased.
Glomerular and tubulointerstitial damage, hypertension,
proteinuria, and the deterioration of renal function resulting
from renal ablation were all similarly and significantly
improved with both treatment doses. These studies suggest
that the beneficial effects of vitamin D receptor activators in
experimental chronic renal failure are due, at least in part, to
down-regulation of the renal renin-angiotensin system.
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The increase in end-stage renal disease constitutes a world-
wide public health problem.1,2 Irrespective of the primary
cause of chronic kidney disease, a reduction in nephron units
leads to a progressive loss of the remaining nephrons that, if
unchecked, results in end-stage renal disease. The pathophy-
siology of this process involves a self-maintaining cycle of
glomerular and tubulointerstitial (TI) damage whereby the
hemodynamic and proinflammatory actions of an activated
renal renin–angiotensin system (RAS) has a pivotal role.3,4
Hence, therapeutic interventions aiming at blocking angio-
tensin II (ANG II) activity represent a strategic cornerstone
designed to halt the progression of chronic kidney disease.5
Other treatment approaches have met with varying degrees of
success6 and among them, the potential value of vitamin D
and its active metabolites has recently been the matter of
considerable interest. In addition to its primary role in
calcium homeostasis and bone mineralization, the vitamin D
endocrine system has additional physiological functions
involving the immune and cardiovascular system and the
protection of renal cellular integrity.7,8 Most of the
pleiotropic actions of vitamin D and its analogues are
mediated by the vitamin D receptor (VDR), a ligand-
dependent transcription factor belonging to the steroid
nuclear receptor gene family8 and recent clinical and
experimental observations have highlighted the role of the
VDR as a downregulator of the RAS. There is an inverse
relationship between vitamin D and blood pressure and renin
activity, suggesting that vitamin D deficiency may be a
cardiovascular risk factor.9,10 Mice lacking VDR and mice
with inhibited calcitriol synthesis have increased renal mRNA
expression of renin, elevated ANG II levels, hypertension and
cardiac hypertrophy and, conversely, calcitriol injections
suppress renin.11,12 In relation to chronic kidney disease, it
has been shown that deficiencies of 1,25-dihydroxyvitamin
D3 (calcitriol) may contribute to structural and functional
deterioration of the kidney. Several studies have shown that
the administration of calcitriol and several of its analogues
attenuate the renal damage in various experimental models of
uremia,13–16 suppress renal inflammation in obstructive
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uropathy,17 and reduce the expression of transforming
growth factor-b (TGF-b).18 However, to our knowledge, the
potential suppression of genes of the RAS by paricalcitol in
the renal ablation model has not been investigated. These
effects could be central to the renoprotective effects of this
vitamin D analogue and could have implications of
considerable clinical significance. The present studies were
designed to evaluate this aspect of paricalcitol treatment in
rats with 5/6 nephrectomy (5/6 Nx).
RESULTS
Physical parameters, renal function, and blood pressure
The baseline characteristics before surgery are shown in
Table 1. No differences in body weight, blood pressure,
plasma creatinine, and urinary protein excretion existed
among the groups at the initiation of the experiments.
The systolic blood pressure (SBP) increased markedly in
all groups with renal ablation (untreated and paricalcitol
treated), and remained significantly higher throughout the
experiment compared to values of sham-operated rats
(Figure 1a). The SBP increment was less pronounced in the
nephrectomized rats treated with either paricalcitol dose (P1 and
P2 groups, Po0.05 or lower vs the 5/6 Nx group, Figure 1a).
Plasma creatinine concentrations increased following renal
ablation and remained higher compared to values in sham-
operated rats throughout the observation period. However,
after the second week, creatinine concentrations declined in
both paricalcitol-treated groups, and stabilized at levels not
significantly different (P¼NS) than those in sham-operated
rats (final creatinine concentration 0.5±0.04 mg/100 ml) and
significantly lower than those in the untreated 5/6 Nx group
(final creatinine concentration 1.59±0.16 mg/100 ml) for the
Table 1 | Baseline physical and renal functional data
Control* (n=10) 5/6 Nx group (n=10) P1 (n=10) P2 (n=5)
Body weight (g) 318±12.0 304.5±7.24 308±9.97 296±15.11
Systolic blood pressure (mm Hg) 130.9±6.0 131.4±2.4 128.8.1±1.54 130.9±2.1
Plasma creatinine (mg/100 ml) 0.39± 0.03
(n=8)
0.34±0.03 0.30±0.02 0.26±0.02
Proteinuria (mg per 24 h) 2.10±0.23
(n=9)
1.69±0.15 1.73±0.32 1.42±0.24
P1 and P2 groups had 5/6 nephrectomy and were assigned to receive paricalcitol, 0.1 (P1), or 0.3 (P2) mg/kg, 3 times per week intraperitoneally.
*Control groups are sham-operated rats; n, number of rats as indicated in the corresponding groups or, if different, shown in the corresponding test line. Data are mean±s.e.
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Figure 1 | Systemic blood pressure and renal functional determinations in rats with renal ablation. Groups represent untreated
(5/6 Nx), treated with low (P1¼ 0.1mg/kg, 3 times per week intraperitoneally) or high-dose paricalcitol (P2¼ 0.3 mg/kg, 3 times per week
intraperitoneally) and sham-operated rats. (a) The SBP increased in all groups with renal ablation compared to sham rats, but less
pronounced in rats treated with either paricalcitol dose (P1 and P2 groups); a, SBP significantly higher than the other groups (Pp0.01),
b, Sham-operated rats had lower SBP than the rest (Pp0.05). (b) Plasma creatinine, initially elevated in all groups with renal ablation,
promptly declined after the second week in paricalcitol-treated rats to levels comparable to sham rats and significantly lower than in
nontreated 5/6 Nx rats. Asterisks (***) represent higher that the rest (Po0.001; a, lower than the rest (Pp0.05). (c) Proteinuria increased
progressively in all nephrectomized groups but was distinctly lower in the groups treated with paricalcitol; a, higher than sham and
P1 (Pp0.05), b, significantly higher (5/6 Nx) or lower (Sham) than the rest (Pp0.05). Data in the figure are mean±s.e.
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remaining of the study (Po0.01). Final plasma creatinine
concentrations were essentially similar in the groups treated
with either lower (P1, 0.67±0.04 mg/100 ml) or higher (P2,
0.76±0.07 mg/100 ml) doses of paricalcitol (Figure 1b).
Sequential determinations of calcium concentrations at
2-week intervals in paricalcitol-treated animals ranged from
8.5 to 10.2 mg/100 ml. The plasma concentrations of Ca were
similar in all treated groups but were lower in the sham
group (Table 2). Final phosphorus concentrations were
unmodified by paricalcitol treatment and remained at similar
levels in all experimental groups (Table 2).
The development of proteinuria was markedly reduced
with the administration of paricalcitol (Figure 1c). Protei-
nuria increased progressively in all groups, but was distinctly
lower in the groups treated with paricalcitol where by week 8
a reduction 450% occurred compared to the untreated 5/6
Nx group (Po0.01)
Anatomical and histological studies
Sham-operated rats had an increment (Po0.01) in body
weight of 60.5±14.42 g (Table 2) from the values at the
initiation of the experiment shown in Table 1. In contrast,
body weights did not increase significantly in nephrecto-
mized rats and were similar in P1, P2, and 5/6 Nx groups at
the end of the experiment (Table 2). Mean weight values of
the remnant kidney at the end of the experiment were
essentially similar in the 5/6 Nx, P1, and P2 groups and the
estimated hypertrophy during the 8-week post-renal ablation
was somewhat lower but not significantly different in the
paricalcitol-treated groups (Table 2). Histological studies
demonstrated important renoprotection with the adminis-
tration of paricalcitol, as evidenced by the reduced glomer-
ular sclerosis and TI damage scores in the paricalcitol-treated
rats compared to nontreated 5/6 Nx uremic rats (Table 2).
Real-time reverse transcriptase-polymerase chain reaction
and protein expression
The mRNA expression and their protein products (western
blot) of components of the RAS are shown in Figures 2 and 3,
Table 2 | Final anatomical, biochemical, and histological data
Controla (n=10) 5/6 Nx (n=10) P1 (n=10) P2 (n=5)
Body weight (g) 368.5±10.16 332±19.48 337±20.30 298.6±23.8
Remnant kidney weight (g) — 1.53±0.12 1.60±0.11 1.57±0.10
Percent of body weight — 0.44±0.02 0.47±0.04 0.54±0.06
Remnant kidney hypertrophy (%) — 51.3±8.60 42.6 ±14.87 40.3±11.67
Glomerulosclerosis index (0–400) 5.3±1.41 47.3±8.41x 15.4±2.31 24.2±4.1
Tubulointerstitial damage score (0–4) 0.5±0.20 5.0±1.05s 2.2±0.46 2.5±0.25
Plasma calcium concentration (mg/100 ml) 8.26±0.13K
(n=5)
9.90±0.31
(n=4)
9.98± 0.42
(n=6)
9.88±0.18
Plasma phosphorus concentration (mg/100 ml) 6.7±0.22
(n=5)
6.5±0.56
(n=4)
6.7±0.66
(n=6)
5.9±0.79
P1 and P2 groups were rats with 5/6 nephrectomy (5/6 Nx) that received 0.1 or 0.3 mg/kg, respectively of paricalcitol intraperitoneally three times weekly for 8 weeks.
aControl groups are sham-operated rats. Data are mean±s.e. Number of determinations correspond to the number of rats in each group except when specifically shown in
parenthesis.
xPo0.001 vs Sham and P1 and Po0.05 vs P2.
sPo0.01 vs Sham and Po0.05 vs P1.
KPo0.05 vs all others.
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Figure 2 | Activation of the RAS and vascular endothelial
growth factor in the kidney of rats with chronic renal
insufficiency. After 8 weeks of renal ablation, renal tissues were
harvested for total RNA isolation. The mRNA levels of (a)
angiotensinogen, (b) renin, (c) renin receptor, (d) angiotensin II
type 1 receptor (AT1R), (e) angiotensin converting enzyme (ACE),
and (f) VEGF were determined by real-time RT-PCR. The relative
amount of the sample mRNA was normalized to the b2-
microglobulin mRNA. *Po 0.05 vs 5/6 Nx; **Po0.01 vs 5/6 Nx;
***Po 0.001 vs 5/6 Nx. Data are presented as values relative to
the 5/6 Nx group, and are expressed as mean±s.e. P1 and P2
groups as defined in Table 2.
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respectively. The mRNA expression of angiotensinogen
(Figure 2a), renin (Figure 2b), and renin receptor (Figure
2c) were significantly reduced by paricalcitol treatment. The
suppressive effects of paricalcitol treatment were more
prominent for angiotensinogen and renin in the high-dose
paricalcitol group (P2). Angiotensin type 1 receptor (AT1R;
Figure 2d) and angiotensin-converting enzyme (ACE;
Figure 2e) mRNAs were not modified by paricalcitol
treatment. The mRNA expression of vascular endothelial
growth factor (VEGF) was also reduced by paricalcitol
treatment (Figure 2f).
Western blot studies demonstrated reduction of the
protein expression of renin (Figure 3a), renin receptor
(Figure 3b), AT1R (Figure 3e), and VEGF (Figure 3d) in
the remnant kidney of paricalcitol-treated animals. The
protein expression of angiotensinogen was not tested because
the appropriate antibody is not commercially available. Renal
expression of TGF-b was, as expected, reduced by paricalcitol
treatment (Figure 3c).
DISCUSSION
The present study was designed with the hypothesis that
paricalcitol abrogates the progressive renal damage and
dysfunction associated with renal mass reduction by
suppressing genes of the RAS. The novel findings of the
study are the demonstration that paricalcitol treatment
reduces mRNA levels and protein expression of angiotensi-
nogen, renin, renin receptor, and VEGF in the 5/6
nephrectomized rats in association with the previously
known beneficial effects of vitamin D on the histological
and functional deterioration of the kidneys.
Vitamin D deficiency occurs early in chronic kidney
disease19 and the administration of active vitamin D in
experimental animal models13–16 and in clinical trials20
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Figure 3 | Expression of RAS genes, TGF-b, and vascular endothelial growth factor in kidney tissues of rats with chronic renal
insufficiency. The protein expression of (a) renin, (b) renin receptor, (c) TGF-b, (d) VEGF, and (e) angiotensin II type 1 receptor (AT1R) were
analyzed by western blotting in sham, 5/6 nephrectomized (untreated), and low-dose paricalcitol-treated rats (P1¼ 0.1 mg/kg, 3 times per
week intraperitoneally) after 8 weeks of renal ablation. *Po0.05 vs 5/6 Nx; **Po0.01 vs 5/6 Nx. Data are mean±s.e.
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resulted in attenuation of renal histological abnormalities
and improvement of proteinuria21 or stabilization of renal
dysfunction without adverse effects on the progression of
renal insufficiency.20 Previous studies on the renoprotective
effects of activated vitamin D focused on its antiproliferative
properties in in vitro cell preparations,22 on the reduction of
mesangial proliferation and glomerulosclerosis in the anti-
Thy-1 glomerulonephritis,23 and on the reduced renal
expression of TGF-b in the renal ablation model.13,14
Kuhlmann et al.24 identified the podocyte as an important
target for the action of 1,25-dihydroxyvitamin D3 and recent
studies by Mizobuchi et al.18 extended these observations
showing that blood pressure control with angiotensin-
converting enzyme inhibition amplifies the TGF-mediated
renoprotective effects induced by the vitamin D analogue
paricalcitol. The present studies confirm the renoprotective
effect of paricalcitol in the renal ablation model. The degree
of renoprotection and particularly the reduction in protei-
nuria with paricalcitol in our study is somewhat greater than
that found by Hirata et al.14 using the analogue 22-
oxacalcitriol, but the studies are not strictly comparable as
the renal failure 8 weeks after renal ablation in their study was
less severe than in ours.
The severity of hypertension observed in the untreated 5/6
Nx group here is similar to previous studies from our
laboratory25 and by others18 in this model of renal ablation.
Both paricalcitol-treated groups displayed significantly lower
SBP readings compared to the untreated 5/6 Nx group, and
in those treated with the higher paricalcitol dose, the BP did
not differ from sham rats (Figure 1a). Studies in the literature
have also reported variable changes in blood pressure as a
result of modification in vitamin D activity. In nonuremic
VDR-null animals, the increased activity of the RAS is
associated with hypertension11 but in rats with renal mass
reduction, Schwarz et al.13 and Mizobuchi et al.18 noted that
neither calcitriol nor paricalcitol had a significant effect on
the SBP, whereas others have noted either modest ameliora-
tion,15 or even increased blood pressure with calcitriol.26
Probably the conflicting results are related to the opposing
interplay between a reduced activity of the RAS and the renal
mass reduction which, in turn, engage a multiplicity of
mechanisms involved in the pathogenesis of hypertension.27
The improvement in renal functional parameters (Figure
1a–c) reflected the histological improvement (Table 2), as
evidenced by the lower glomerular sclerosis index, and in
particular the lower score of TI injury in animals that
received paricalcitol. These findings are in concordance with
the demonstration of inhibition by paricalcitol of TGF-b-
induced epithelial to mesenchymal transition and myofibro-
blast accumulation.17 Overproduction of TGF-b is almost
universally observed in models of experimental renal failure,
is known to have a crucial role in renal fibrogenesis, and
blockade of its activity is associated with attenuation of
progressive renal failure.28,29 We also noted a marked
overexpression of TGF-b in the renal tissues of 5/6 Nx rats
that was significantly attenuated by the administration of
paricalcitol (Figure 3c). Other investigators have previously
demonstrated pronounced inhibition of the TGF-b mRNA
levels in 5/6 Nx rats treated with paricalcitol18 and in
adriamycin-induced renal failure with another VDR analog,
22-oxacalcitriol.15
The RAS has a central role in causing renal deterioration
through hemodynamic, proinflammatory, and profibrotic
mechanisms.28 Our novel observations of a marked reduction
in the kidney of the mRNA angiotensinogen, renin, and renin
receptor expressions in the paricalcitol-treated groups are of
particular relevance in relation to the fact that the local
intrarenal RAS may operate independently from and some-
times contrary to its systemic counterpart30,31 and that
proximal tubular cells actively produce ANG II and secrete
angiotensinogen into the tubular lumen.31 We did not
measure plasma renin levels in the present investigations,
but the surgical renal ablation model used in this study is
typically a low-plasma renin model and therefore systemic
RAS activity should not be having a preeminent role in the
observed intrarenal RAS changes.
We restricted reverse transcription (RT)–PCR determina-
tions to the animals with renal ablation aiming to focus on
the effects of the VDR activator in renal insufficiency; sham-
operated animals were not studied. However, previous
studies by other investigators have demonstrated by RT–PCR
the suppressive effects of calcitriol11 and paricalcitol32 on the
renal RAS of normal rodents and studies by Gilbert et al.33
have shown that following subtotal nephrectomy, renin
synthesis is suppressed at the juxtaglomerular apparatus
but appears de novo in the tubular epithelium accompanied
by concomitant de novo appearance of ANG II in the renal
tubule. The increase in renin was particularly apparent in
areas of marked injury compared with regions in which only
mild structural disruption was present.33 Consistent with
their findings,33 in the present study paricalcitol treatment
resulted in reduced renin mRNA expression in association
with preservation of TI integrity.
The renal RAS, specifically the renal expression of renin, is
known to be mediated by calcium metabolism or parathyroid
hormone.34 Although ionized calcium or parathyroid
hormone were not determined in the present experiments,
Li et al.11 have clearly demonstrated that normalization of
hypocalcemia and increased parathyroid hormone by dietary
intervention in VDR-ablated animals had no effect on the
markedly elevated renal renin expression. More recently,
administration of paricalcitol to normal mice resulted in a
significant suppression of renal renin expression in the
absence of hypercalcemia at doses (0.3 mg/kg, like our P2
group) 10-fold above necessary for parathyroid hormone
suppression.32 The doses of paricalcitol employed in our
study were non-hypercalcemic35 as evidenced by the normal
total serum Ca concentrations throughout the observation
period. High calcium diets can also reduce the expression of
RAS components in renal tissues of rats with experimental
renal failure,36 but all animals in the present study were fed a
normal Ca intake. In addition, suppression of renal renin
1398 Kidney International (2008) 74, 1394–1402
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expression was evident in both paricalcitol-treated animals
compared to the nontreated nephrectomized group despite
similar plasma calcium concentrations in all three groups
(Table 2). Thus, we believe that the observed changes in renal
RAS genes are unlikely the result of changes in calcium
metabolism.
The reduced mRNA levels and protein expression of renin
receptor observed in renal tissues of the paricalcitol-treated
rats may also offer relevant benefits over other well
recognized anti-angiotensin therapies, such as AT1R blockers,
which may increase receptor-mediated renin activity.37
Furthermore, paricalcitol may also suppress the progression
of renal damage by mechanisms independent of ANG II as
angiotensin-converting enzyme inhibitors and AT1R blockers
do not modify the increase in TGF-b synthesis induced by
renin.38 Therefore, paricalcitol administration may provide a
dual renoprotective effect, namely by way of reduced ANG II
generated through the intrarenal RAS cascade, as well as a
result of its direct suppressive effects on the renin receptor-
mediated TGF-b generation. The reduction of the AT1R
protein expression does not appear to be related to a
paricalcitol-induced downregulation in its mRNA expression.
It is possible that protein stability may be affected while
mRNA levels remain unchanged. It should be noted that in
rats with 5/6 Nx, renal AT1R expression is increased in the TI
compartment and, particularly, in the interstitial component,
where its expression is reduced by angiotensin receptor
blockers and anti-inflammatory agents.39 Therefore, it is
reasonable to assume that the reduction in AT1R obtained
with paricalcitol treatment is the result of a lesser interstitial
inflammation and expansion resulting from this therapy
(Table 2). Whether post-translational factors are involved in
the reduced AT1R expression cannot be ascertained from the
present experiments. Similarly, the suppressed renin expres-
sion found in the P1 group (Figure 3) while renin mRNA
levels were significantly reduced only in the P2 group, are
likely due to larger variability in the renin mRNA in the P1
group (Figure 2).
A special note deserves the new observation that
paricalcitol treatment reduces mRNA and protein expression
of VEGF in the kidney. In renal disease, VEGF has been
reported to have paradoxical effects that have been explained
by the uncoupling of its activity to the endothelial nitric
oxide axis.40 This growth factor is prominently expressed in
glomerular podocytes and in tubular epithelial cells and its
increased expression causes glomerular hypertrophy and
proteinuria.41 In the renal ablation model, inhibition of
VEGF results in amelioration of glomerular hypertrophy and
reduction of proteinuria.42 As the synthesis of VEGF is
stimulated by ANG II through the activation of the p38
MAPK pathway43 it is reasonable to suggest that the
reduction in VEGF synthesis by paricalcitol is a consequence
of the inhibition of the RAS and that VEGF suppression
contributed to the histological and functional improvement.
In summary, the present study demonstrates that
paricalcitol suppresses genetic expression of key components
of the RAS and VEGF in the remnant kidney and confirms
that early administration of paricalcitol is capable of halting
the otherwise unabated histological and functional deteriora-
tion of the kidney.
MATERIALS AND METHODS
Experimental animals and design
The studies were performed in male Sprague–Dawley rats [Instituto
Venezolano de Investigaciones Cientı´ficas (IVIC), Los Teques, Altos
de Pipe, Venezuela] that weighed 265–395 g at the beginning of the
experiments. They were housed in temperature-controlled facilities,
fed standard rat chow (Ratarina, Protinal, Valencia, Venezuela) with
free access to water, and handled in accordance with institutional
guidelines of animal care. The protocol of the experiments was
approved by the Committee of Animal Care and Use of the IVIC-
Zulia. Rats were assigned to have either renal ablation by 5/6 Nx or
to have a sham operation. Renal ablation was performed by surgical
resection of the right kidney and the two poles of the left kidney, and
the kidneys and poles removed were weighted immediately. All
surgical procedures as well as killing at the end of the experiments
were performed under diazepam/ketamine general anesthesia.
Postoperative pain was relieved by a protocol administration of a
single dose of diazepam (1 ml of a 1 mg/ml solution) after the rat
was completely awake after surgery.
Renal ablation has a 20–30% surgical mortality in our
laboratories. Four days after surgery, the animals that survived
renal ablation were assigned to the following experimental groups :
(1) P1 group (n¼ 10) received paricalcitol 0.1 mg/kg, three times a
week by intraperitoneal (i.p.) injection; (b) P2 group (n¼ 5)
received i.p. paricalcitol 0.3 mg/kg at the same intervals. This group
was initially of six animals but one animal from this group died in
the 8th week before killing and was excluded from analysis; and (3)
5/6 Nx group (n¼ 10) received vehicle three times a week and (4)
Sham-operated group (n¼ 10) consisted of rats that underwent
similar surgical incision, the kidneys were manipulated but left
intact and the wound was closed. The doses of paricalcitol employed
in the present study have been previously demonstrated to
effectively control the development and treatment of secondary
hyperparathyroidism without elevations in serum ionized calcium in
the 5/6 Nx model35 and are within the therapeutic dose-range
currently used in clinical practice.44
The administration of paricalcitol or vehicle was begun 5–6 days
after surgery and maintained for 8 weeks. Plasma samples for
creatinine, calcium, and 24 h urine protein were evaluated every 2
weeks by autoanalyzer methodology as previously described.25
Weight was determined at the beginning, at 4 weeks, and after 8
weeks and SBP was determined every 2 weeks. At killing, remnant
kidneys were harvested, weighted and processed for histology and
mRNA determinations. Hypertrophy of the remnant kidney was
estimated assuming that the kidney that remained after 5/6 Nx
represented 1/6 of the weight of the removed renal tissue.
Blood pressure measurements
The SBP was determined by tail-cuff plethysmography (IITC Life
Science Inc., Woodland Hills, CA, USA). As described in previous
communications,45–48 animals had been preconditioned to the
procedure. For this purpose, in 4–5 occasions before the experiments
were begun the rats were placed in the restrainer, allowed to rest for
10–15 min in a quiet ambient and the cuff was inflated several times
before the animals were returned to their cages. During the
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experiments, a similar procedure was followed and after stable
values were obtained, the average of three determinations of the
systolic and mean arterial pressures were recorded.
Renal histology
Paraffin-embedded biopsies stained with periodic acid-Schiff,
hematoxylin and eosin, and trichrome stains were used for light
microscopy studies. Severity of glomerular sclerosis was evaluated
using an index score reported in previous communications45–48 by
grading glomerular involvement in a scale from 0 (normal) to 4þ
(sclerosis occupying more than 75% of the glomerular tuft) and
calculating a score using the following formula: [(1 n glomeruli
with 1þ )þ (2 n glomeruli with 2þ )þ (3 n glomeruli with
3þ )þ (4 n glomeruli with 4þ )] 100/total number of glomer-
uli examined. The TI damage was graded as in previous
communications45–48 according to the extent of damage (infiltra-
tion, fibrosis, tubular dilatation) in successively evaluated fields in
the entire renal cortex (0¼ normal, 1þp10%, 2þ ¼ 10–25%,
3þX25–50%, 4þX50–75% and 5þX75%). All histological
studies were performed blinded as to the group in which the biopsy
was obtained. Computer-assisted image analysis was performed
employing an Olympus BX51 System Microscope (Olympus Corp.,
Miami, FL, USA) and the DP70 microscope digital camera with
Sigma Pro (Leesburgh, VA, USA) image analysis software as in
previous work.49–51
Real-time PCR
PCR studies were performed in remnant kidneys harvested from 5
to 6 rats of each experimental group immediately placed in
RNALater solution (Ambion, Austing, TX, USA) to store at
80 1C. Total RNAs were extracted from these tissues using
TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instruction. First-strand cDNAs were reverse tran-
scribed from total RNAs using MML-V reverse transcriptase
(Invitrogen) and hexanucleotide random primers. PCR was
performed in an Applied Biosystems 7300 Real-Time PCR System
using an SYBR green PCR reagent kit (Applied Biosystems, Foster
City, CA, USA), and the change in each mRNA expression was
determined based on the formula 2 DDCtð Þas previously described.52
The relative amount of the sample mRNA was normalized to the
b2-microglobulin mRNA. The PCR primers used in this study are
listed in Table 3.
Western blot
Western blot analyses were performed in paraffin-embedded kidney
tissues after extraction according to the method described by Ikeda
et al.53 As the renal functional and histopathological findings were
comparable in both paricalcitol-treated groups, protein expression
was analyzed by western blotting in the same tissues of the P1 group
(n¼ 5–6) where RT–PCR were measured. As described in a recent
publication,54 kidney homogenates were prepared in lysis buffer
(50 mN Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, and
0.1% SDS) containing protease inhibitor. After centrifugation
(3000 g for 30 min, 4 1C) protein determination was determined in
the supernatant. Samples were resuspended in 25 ml of 60 mM Tris-
HCL (containing 25% glycerol, 2% SDS, 14.4 mM 2-mercapto-
ethanol, and 0.1% bromophenol blue), heated at 65 1C, centrifuged
(3000 g for 1 min), loaded on 10% separating gel and eletrophoresed
at 100 mV. Proteins were then transferred to nitrocellulose
membranes (Bio-Rad). After blocking with nonfat dry milk (5%)
in Tris-buffered saline containing 0.1% Tween 20 for 1 h at room
temperature, membranes were incubated overnight at 4 1C with the
primary antibodies. Membranes were then washed in tris buffer-
saline (TBS) with 0.1% Tween 20 and incubated with the secondary
antibody. Peroxidase activity was developed with 3,30-diamino-
benzidine with ion metal enhancement and protein levels were
quantified in the Image J program. Primary antibodies used were:
anti-b actin polyclonal antibody (Assay Designs, Ann Arbor, MI,
USA); anti-renin antibody (G-18; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-renin receptor antibody (K-19; Santa Cruz
Biotechnology), anti TGF-b (Promega, Madison, VA, USA), and
anti-VEGF (Santa Cruz Biotechnology). Secondary antibodies were
horseradish peroxidase-conjugated goat anti-rabbit immunoglobu-
lin G (Stressgen Bioreagents, Glanford, Canada) and donkey anti-
goat (Santa Cruz Biotechnology), all used at 1:1000 dilution in
Tris-buffered saline containing 5% dry milk and 0.1% Tween 20.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version
4.00 for Windows, GraphPad Software, San Diego, CA, USA. All
data are given as mean±s.e. Comparison between groups was made
using one-way multigroup analysis of variance tests followed by
Tukey–Kramer post tests. Serial changes were evaluated with
repeated-measures analysis of variance and changes with respect to
baseline with Dunnett tests. Two-tailed P-values o0.05 were
considered significant.
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Table 3 | Primers used in real time RT-PCR amplification
Gene Primer nucleotide sequences
Renin Forward 50-AGGATCAGTGCTGAATGGGGTGA-30
Reverse 50-GGTTGTGAATCTCACAGGCAGTGT-30
Renin receptor Forward 50-CCCTTTGGAGAATGCAGTTCCCT-30
Reverse 50-GAAACAGGCGATTACGGAGCTGA-30
Angiotensinogen Forward 50-CAGCACGACTTCCTGACTTGGAT-30
Reverse 50-GGATGCTGTTGAGAACCTCTCCCA-30
VEGF Forward 50-TTCATGGACGTCTACCAGCGCA-30
Reverse 50-TCCGCATGATCTGCATAGTGACGT-30
TGF-b1 Forward 50-CATTCGGGAAGCAGTGCCAGAA
Reverse 50-CCCTGTATTCCGTCTCCTTGGTTCA
b2 Microglobulin Forward 50-ATCTGTCCTTCAGCAAGGACTGGT-30
Reverse 50-TGGTCCAGATGATTCAGAGCTCCA-30
VEGF, vascular endothelial growth factor; TGF-b, transforming growth factor-b.
All primers were designed according to the cDNA sequence of each gene deposited
in the GenBank database.
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format at the annual meeting of the American Society of Nephrology,
San Francisco, CA, USA in October 2007.
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